German drugs watchdog finds "hint of considerable added benefit" for Pfizer's Inlyta

9 January 2013

The German Institute for Quality and Efficiency in Health Care (IQWiG) has examined the added benefit of US drug behemoth Pfizer’s (NYSE: PFE) kidney cancer drug Inlyta (axitinib) under the Act on the Reform of the Market for Medicinal Products (AMNOG), finding. “a hint of a considerable added benefit) over the drug sorafenib (Bayer’s Nexavar), because the risk of certain side effects is lower with axitinib. In contrast, an added benefit in comparison with everolimus is not proven, because of the lack of suitable data.

Inlyta) has been approved in the European for the treatment of people with advanced kidney cancer (advanced renal cell carcinoma) in whom previous treatment with sunitinib or a cytokine was unsuccessful (The Pharma Letter September 5, 2012) and was approved in the USA in January 2012.

Axitinib compared with everolimus or sorafenib

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK